|
1. Biologie
|
|
|
|
2. Etiologie
|
|
|
|
3.3 Prévention - Vaccins
|
|
|
|
4.10 Dép., diag. & prono. - FDA, EMA, NICE,...
|
|
|
|
5.10 Traitements - Essais
|
|
|
|
5.12.2 Immunothérapies - CAR-T
|
|
|
At Seattle Children’s, Another Piece of Ambitious CAR-T Plan in Place [Xconomy]
|
|
|
|
|
|
As
part of their plan to prevent relapses, Seattle Children’s researchers
want to find out if a different tumor target, CD22, can be an Achilles’
heel of tumors that bounce back after a CD19-directed attack. In about a
quarter of all patients treated with CD19-directed T cells, the cancer
mutates and comes back without CD19, leaving them invisible to the T
cells.
|
|
|
|
|
|
|
|
|
|
Message from the President [EBMT]
|
|
|
|
|
|
EBMT
is committed to allow access of all patients to CAR-T cell therapy.
However, the announced price tags for such products appear to be quite
prohibitive.
|
|
|
|
|
|
|
5.12.8 Immunothérapies - Economie
|
|
|
|
5.3.4 Traitements - AMM (FDA, EMA)
|
|
|
|
|
|
|
|
|
5.4 Traitements - Economie
|
|
|
|
5.8.2 ASH - Pharma
|
|
|
|
6. Lutte contre les cancers
|
|
|
|
6.11 Patients
|
|
|
|
6.4 Médico-éco
|
|
|
|
6.6 Publications
|
|
|
|
|
6.7.1 Bioinformatique
|
|
|